Premium
Updated survival analyses after prolonged follow‐up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
Author(s) -
Jagannath Sundar,
Barlogie Bart,
Berenson James R.,
Siegel David S.,
Irwin David,
Richardson Paul G.,
Niesvizky Ruben,
Alexanian Raymond,
Limentani Steven A.,
Alsina Melissa,
Esseltine DixieLee,
Anderson Kenneth C.
Publication year - 2008
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2008.07359.x
Subject(s) - bortezomib , refractory (planetary science) , multiple myeloma , medicine , oncology , multicenter study , materials science , randomized controlled trial , composite material
Summary The Clinical Response and Efficacy Study of Bortezomib in the Treatment of Relapsing Multiple Myeloma (CREST) demonstrated substantial activity with two dose levels of bortezomib (1·0 and 1·3 mg/m 2 ), alone or with dexamethasone, in relapsed or refractory multiple myeloma. We present updated survival analyses after prolonged follow‐up (median >5 years). One‐ and 5‐year survival rates were 82% and 32%, respectively, in the 1·0 mg/m 2 group ( n = 28), and 81% and 45%, respectively, in the 1·3 mg/m 2 group ( n = 26). Notable survival, response, and time‐to‐progression data suggest that a bortezomib starting dose of 1·3 mg/m 2 is preferred. If bortezomib dose reduction is required, the 1·0 mg/m 2 dose still offers patients a substantial survival benefit.